The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be implemented over the next 18 months. Published first ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts.

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Adding fluorine to drug molecules can be tricky, but is often worthwhile. Rachel Brazil talks to the chemists trying to tame ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

Dennis Morris is best known for his images of Lydon’s former band the Sex Pistols and Bob Marley. Lydon claims that he came up with the distinctive PiL logo in the shape of a pill, and asked ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...

mapping gene expression to particular locations in the brain to try to identify and validate new drug targets for the neurodegenerative disorder. GSK is paying out €33.5 million in cash to get ...